Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 351 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Test formulation Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Relative Bioavailability of Entrectinib Capsule Formulations F1 and F06 Under Fed Conditions in Healthy Participants

NCT03796260
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Entrectinib Test Formulation (F1), Entrectinib Reference Formulation (F06)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 20, 2026, 6:46 PM EDT
Recruiting Phase 3 Interventional

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

NCT07388524
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma
Interventions
Atezolizumab, Atezolizumab and Recombinant Human Hyaluronidase, Biospecimen Collection, Computed Tomography, Patient Observation
Biological · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
105
States / cities
Beverly Hills, California • Los Angeles, California • Tarzana, California + 88 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 6:46 PM EDT
Recruiting Phase 2 Interventional

5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss

NCT07044310
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Hormone Receptor-Positive Breast Carcinoma
Interventions
Biospecimen Collection, Bone Mineral Density Test, Questionnaire Administration, WBF-038
Procedure · Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 20, 2026, 6:46 PM EDT
Completed Phase 1 Interventional

Multiple Dose, Dose Escalation Study of Varenicline Controlled Release Formulation in Adult Smokers

NCT00527150
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline Tartrate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
East Grand Forks, Minnesota • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Oct 20, 2026, 6:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbriet in Healthy Volunteers

NCT05428150
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Esbriet 267 MG Oral Capsule, EXCL-100, 600 MG Oral Tablet
Drug
Lead sponsor
Excalibur Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 20, 2026, 6:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study Testing Ketamine Sublingual Wafer After Wisdom Tooth Extraction

NCT02356965
View directory record Official record
Conditions
Pain
Interventions
Ketamine, Placebo (for Ketamine)
Drug
Lead sponsor
iX Biopharma Ltd.
Other
Eligibility
18 Years to 38 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Oct 20, 2026, 6:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices

NCT06003465
View directory record Official record
Conditions
Healthy
Interventions
LY3437943, Test, Reference
Drug · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Miami, Florida • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 20, 2026, 6:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Taste Test of a New Formulation of Sildenafil (Revatio)

NCT00768573
View directory record Official record
Conditions
None Volunteer
Interventions
sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 20, 2026, 6:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects

NCT03135509
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-220
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 20, 2026, 6:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Human Photoallergy Test

NCT02750449
View directory record Official record
Conditions
Sunscreening Agents
Interventions
Sun screening Sport Lotion, (BAY987516), Untreated skin
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 20, 2026, 6:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets

NCT00853216
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone hydrochloride tablet 30 mg, Roxicodone™ tablet 30 mg
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 20, 2026, 6:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Benazepril HCl 40 mg Tablets, Fasting

NCT00836576
View directory record Official record
Conditions
Healthy
Interventions
Benazepril HCl 40 mg Tablets, Lotensin® 40 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 20, 2026, 6:46 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Glycine vs Placebo for the Schizophrenia Prodrome

NCT00291226
View directory record Official record
Conditions
Schizophrenia Prodrome
Interventions
Glycine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
13 Years to 35 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 20, 2026, 6:46 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks

NCT03954743
View directory record Official record
Conditions
Infections, Rotavirus
Interventions
PCV-free liquid formulation of GSK's oral live attenuated HRV vaccine, Lyophilized formulation of GSK's oral live attenuated HRV vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,351 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
19
States / cities
Birmingham, Alabama • Colorado Springs, Colorado • Louisville, Kentucky + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 20, 2026, 6:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Iontophoretic Application of Terbinafine Gel to the Large Toe Nail

NCT00768768
View directory record Official record
Conditions
Onychomycosis
Interventions
Electrokinetic Transungual System (ETS) - Terbinafine Gel, ETS-Terbinafine Gel
Other
Lead sponsor
Transport Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Oct 20, 2026, 6:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042

NCT07222878
View directory record Official record
Conditions
Epilepsy, Alzheimer Disease, Epilepsy Intractable
Interventions
NPT 2042 (Reference formula/Formulation 1), NPT 2042 (Test formula/Formulation 2)
Drug
Lead sponsor
NeuroPro Therapeutics, Inc.
Industry
Eligibility
19 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 20, 2026, 6:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Photoallergic Potential of 6% Bemotrizinol

NCT05254912
View directory record Official record
Conditions
Photoallergic Response
Interventions
6% Bemotrizinol in sunscreen formulation, 6% Bemotrizinol in petrolatum, Vehicle
Drug · Other
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 20, 2026, 6:46 PM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

NCT04310007
View directory record Official record
Conditions
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Docetaxel, Echocardiography Test, Gemcitabine Hydrochloride, Nab-paclitaxel, Nivolumab, Paclitaxel, Ramucirumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
611
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 392 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 6:46 PM EDT
Recruiting Phase 2 Interventional

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

NCT03907475
View directory record Official record
Conditions
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Capecitabine, Carboplatin, Computed Tomography, Durvalumab, Echocardiography Test, Gemcitabine Hydrochloride, Nab-paclitaxel, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 6:46 PM EDT
Completed Not applicable Interventional

Tolerability Study of Panosyl Isomaltooligosaccharides (PIMO), in Subjects With Chronic Idiopathic Constipation (CIC)

NCT05129618
View directory record Official record
Conditions
Constipation Chronic Idiopathic
Interventions
MHS 1031, placebo
Dietary Supplement · Other
Lead sponsor
Microbiome Health Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Manassas, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 20, 2026, 6:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability For Palbociclib Formulations

NCT02083640
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib Formulation Reference, Palbociclib Formulation Test
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 20, 2026, 6:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of a Gel Sunscreen in Controlled Use Conditions (208/2016)

NCT03012347
View directory record Official record
Conditions
Sunscreening Agents
Interventions
BAY987517, BullFrog Gel Sunscreen Land Sport SPF-50
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 20, 2026, 6:46 PM EDT
Recruiting Phase 1Phase 2 Interventional

Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma

NCT07136181
View directory record Official record
Conditions
Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic, Uveal Melanoma, Recurrent, Eye Cancer, Intraocular Melanoma, Eye Cancer
Interventions
NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.
Drug
Lead sponsor
Novelwise Pharmaceutical Corporation
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Scottsdale, Arizona • Denver, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 20, 2026, 6:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design

NCT06369727
View directory record Official record
Conditions
Erythema
Interventions
MOB015B, MOB015B vehicle, Negative irritant solution of 0.9% saline
Drug
Lead sponsor
Moberg Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 20, 2026, 6:46 PM EDT